Literature DB >> 10471309

Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.

W E Van Nostrand1, M Porter.   

Abstract

Cerebrovascular amyloid beta-protein (A beta) deposition, a key pathological feature of Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis Dutch-type, can lead to intracerebral hemorrhage; however, the mechanism for this remains unclear. Assembled A beta is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro. Herein, we investigated the stimulation of tPA by freshly solubilized A beta 1-40. The rate of tPA stimulation by A beta 1-40 increased dramatically over time, suggesting that A beta may be altered during the course of the reaction. SDS-PAGE analysis showed that A beta 1-40 was cleaved during the course of the reaction. Subsequent studies showed that it was plasmin, the product of tPA activation of plasminogen, that specifically cleaved A beta 1-40 in the amino terminal region between Arg5 and His6. Plasmin effectively cleaved a chromogenic substrate corresponding to this cleavage site in A beta. Circular dichroism spectral analysis showed that A beta 6-40 adopted a strong beta-sheet secondary structure. This truncated A beta 6-40 peptide was a potent stimulator of tPA in vitro. Our results indicate that beta-sheet secondary structure of A beta, which can be promoted by plasmin cleavage, stimulates tPA activity. These findings suggest that pathologic interactions between A beta, tPA, and plasmin in the cerebral vessel wall could result in excessive proteolysis contributing to intracerebral hemorrhages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471309     DOI: 10.1021/bi990610f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  45 in total

1.  Proteolysis in Alzheimer's disease. Can plasmin tip the balance?

Authors:  G Periz; M E Fortini
Journal:  EMBO Rep       Date:  2000-12       Impact factor: 8.807

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 3.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

4.  Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.

Authors:  R-M Liu; T van Groen; A Katre; D Cao; I Kadisha; C Ballinger; L Wang; S L Carroll; L Li
Journal:  Neurobiol Aging       Date:  2009-07-14       Impact factor: 4.673

5.  Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein.

Authors:  Wenjun Li; Ethan Poteet; Luokun Xie; Ran Liu; Yi Wen; Shao-Hua Yang
Journal:  Brain Res       Date:  2011-03-02       Impact factor: 3.252

Review 6.  The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis.

Authors:  William E Van Nostrand
Journal:  Biochim Biophys Acta       Date:  2015-10-27

Review 7.  Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

Authors:  D Allan Butterfield; Miranda L Bader Lange
Journal:  J Neurochem       Date:  2009-09-23       Impact factor: 5.372

Review 8.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

9.  Degradation of amyloid beta protein by purified myelin basic protein.

Authors:  Mei-Chen Liao; Mahiuddin Ahmed; Steven O Smith; William E Van Nostrand
Journal:  J Biol Chem       Date:  2009-08-19       Impact factor: 5.157

Review 10.  Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2012-10-05       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.